| Name | Title | Contact Details |
|---|
Leveraging unique gyroscopic motion, ZAP-X® opens new frontiers in modern radiosurgery. Combining self-shielding technology with high dose rate linear-accelerator delivery, ZAP-X was created to safely treat more patients in more places.
NuView Life Sciences is a Park City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Critical Homecare Solutions is a Conshohocken, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ZipLine® Medical is developing and commercializing innovative tissue repair devices to address the clinical need for rapid, non-invasive and easy-to-use skin closure. ZipLine`s PRELOC™ technology platform provides uniform closure forces while minimizing scar-promoting tension along the wound. Utilizing our patented technology, we believe that physicians can achieve the best of both worlds — the speed of staples with the cosmetic outcome of a meticulous suture closure. Our initial strategy focuses on procedures where the non-invasive, speed and cosmetic benefits of our technology have the greatest impact. Since skin closure is a part of most surgical procedures, our technology platform has broad application across various surgical specialties and emergency medicine. ZipLine Medical was founded in 2009 by Amir Belson, M.D. and is located in Silicon Valley, with access to a wealth of expertise in medical device research and development
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.